ArticleJournal of comparative effectiveness research2025

Cost impact of Bruton's tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia.

Adam S Kittai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.